The data wes presented in a Late-Breaking Science session at the European Society of Cardiology (ESC) Heart Failure Association (HFA) Congress 2026 in Barcelona, Spain.

The randomized, double-blind, placebo-controlled study demonstrated a favorable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement, and rapid and sustained improvements in hemodynamics and in cardiac structure and function, including increases in cardiac output and left ventricular ejection fraction, on top of optimized guideline-directed medical therapy.                     

Late-Breaking Science presentations are reserved for studies of high scientific and clinical importance, reflecting important and timely advances in cardiovascular medicine.

AC01 is a first-in-class, oral ghrelin receptor agonist designed to improve cardiac contractility through enhanced calcium sensitivity.